Please login to the form below

Not currently logged in
Email:
Password:

Pixuvri

This page shows the latest Pixuvri news and features for those working in and with pharma, biotech and healthcare.

CTI launches cancer drug Pixuvri in UK

CTI launches cancer drug Pixuvri in UK

Cell Therapeutics Inc (CTI) has launched its cancer treatment Pixuvri in the UK. ... were later resolved at the end of 2013, meaning Pixuvri is available for reimbursement.

Latest news

  • NICE relents and gives Pixuvri limited backing NICE relents and gives Pixuvri limited backing

    NICE relents and gives Pixuvri limited backing. Recommends Cell Therapeutics drug for an aggressive form of cancer. ... Cell Therapeutics has scraped a limited recommendation from NICE for its non-Hodgkin's lymphoma drug Pixuvri.

  • NICE unmoved by Pixuvri access scheme NICE unmoved by Pixuvri access scheme

    NICE unmoved by Pixuvri access scheme. England’ s HTA body once again denies Cell Therapeutics' blood cancer treatment. ... Cell Therapeutics now has another consultation period in which it can try and convince NICE to recommend Pixuvri.

  • Roche wins conditional EU approval for cancer drug Erivedge Roche wins conditional EU approval for cancer drug Erivedge

    Cell Therapeutics' Pixuvri (pixantrone) for non-Hodgkin B-cell lymphoma.

  • Cell Therapeutics fails to gain NICE backing for blood cancer drug Cell Therapeutics fails to gain NICE backing for blood cancer drug

    Watchdog says not enough evidence to show Pixuvri is more effective than current treatments. ... demonstrates Pixuvri is a cost-effective therapy for this end-of-life disease population,” said Dr James Bianco, president and CEO of Cell Therapeutics.

  • IQWiG rejects Cell Therapeutics' Pixuvri IQWiG rejects Cell Therapeutics' Pixuvri

    IQWiG rejects Cell Therapeutics' Pixuvri. Rules non-Hodgkin lymphoma drug provides 'no additional benefit'. ... We believe Pixuvri offers patients suffering from aggressive NHL a safe and effective therapy, where there currently is no standard of care.".

More from news
Approximately 6 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Oncology drugs under AMNOG

    Pixuvri: Polycomparator segmentation by the G-BA removes statistical power. Cell Therapeutics gained European approval for Pixuvri (pixantrone) in non-Hodgkin’ s B-cell lymphoma, on the basis of a trial ... This exclusion of trial data from other

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GEM Marketing Ltd

GEM, a small but perfectly formed integrated marketing agency servicing the pharmaceutical industry....

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics